UNSPSC 51263174: Timolol hemihydrate

This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C13H24N4O3S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 817W3C6175, chemically known as (s)-1-(tert-butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)-2-propanol hemihydrate, but more generally known as timolol hemihydrate, which bears US NIH Compound Identifier 62933. European Medicines Agency schedules timolol hemihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11069MIG.

Most nations, for tariff purposes, schedule timolol hemihydrate under HS 29349990. SMILES: CC(C)(C)NC[C@@H](COC1C(NSN1)N2CCOCC2)O.CC(C)(C)NC[C@@H](COC1C(NSN1)N2CCOCC2)O.O.

UNSPSC 51263174 Timolol hemihydrate is a Commodity code that in state and local procurement should address pharmaceutical active ingredients and ophthalmic compounds, though recent activity under this code tag shows little alignment with that nominal scope. The single recent solicitation on record—Seminole County, Florida's IFB60459723LAS—requests Naloxone and Safe Drug Deactivation Systems, products unrelated to timolol hemihydrate (a beta-blocker used in eye drops and oral formulations). The mismatch suggests either a tagging error in the source data or that this particular code is not currently in active use for its intended pharmaceutical commodity class in state and local procurement.

Seminole County's July 2026 posting sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually via IFB with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023 (note: the posted date of June 30, 2026, and the due date of July 26, 2023, appear inconsistent in the source). The procurement required e-submission through the county's e-Procurement Portal, drug-free workplace certification, E-Verify compliance, and maintained fixed-fee pricing with workers' compensation and liability coverage. No explicit set-aside designations were noted. This single opportunity provides insufficient evidence of meaningful recent activity under the timolol hemihydrate code in state and local procurement.